Quand et comment traiter les hepatites B et C? [When and how to treat hepatitis B and C?]
Details
Serval ID
serval:BIB_746FE98C8C45
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Quand et comment traiter les hepatites B et C? [When and how to treat hepatitis B and C?]
Journal
Revue Médicale Suisse
ISSN
1660-9379 (Print)
Publication state
Published
Issued date
01/2005
Volume
1
Number
3
Pages
237-41
Notes
English Abstract
Journal Article
Review --- Old month value: Jan 19
Journal Article
Review --- Old month value: Jan 19
Abstract
The introduction of pegylated interferon-alpha (PEG-IFN-alpha) as well as lamivudine and adefovir has greatly improved the perspectives for patients with chronic hepatitis B. In addition, new nucleos(t)ide analogues are currently being evaluated and may allow the development of effective combination therapy regimens in the future. In the absence of resistance development, lamivudine reduces the risk of decompensation and hepatocellular carcinoma in patients with cirrhosis. Current standard therapy of chronic hepatitis C, PEG-IFN-alpha combined with ribavirin, results in a sustained virologic response in 20-80% of patients, depending on the viral genotype and additional factors, such as ethnicity, fibrosis stage, body mass index, viral load, alcohol consumption, and coinfections. Novel antiviral strategies are currently being explored.
Keywords
Antiviral Agents/*therapeutic use
Carcinoma, Hepatocellular/pathology
Drug Administration Schedule
Drug Therapy, Combination
Genotype
Hepatitis B/complications/*drug therapy/pathology
Hepatitis C/complications/*drug therapy/pathology
Humans
Liver Cirrhosis/prevention & control
Liver Neoplasms/prevention & control
Pubmed
Create date
25/01/2008 17:05
Last modification date
20/08/2019 15:32